MyFiziq teams up with Biomorphik to develop on-demand product
MyFiziq Limited (ASX:MYQ) has executed definitive agreements with Biomorphik Pty Ltd (Biomorphik), an Australian-based behavioural change and technology company.
Biomorphik has developed a medical health and wellness platform that is the bridge between medical and health/wellness with the aim of reducing health costs at all levels of society from the individual, to healthcare and insurance systems and governments.
The company has had a surge of interest in its product offering from governments and large corporations across Asia as a result of the current pandemic.
As a consequence of developments relating to the pandemic, Biomorphik has found that consumers, corporations and governments have developed a better understanding of the value of a healthy lifestyle and its impacts on individuals, families, business and economies.
This is an excellent fit with MyFiziq’s body scan technologies that have also come to market at a critical time as the demand for its products are accelerating.
New product to be launched in November
Under the commercial terms of the definitive agreements, Biomorphik and MyFiziq have commenced working together to build and release an initial product by 10 November, 2020.
This will use MyFiziq’s new Body Scan OnDemand product which comprises a set of standalone iOS and Android applications, branded in Biomorphik colours, linked to Biomorphik’s iOS and Android applications via cross-app deep linking.
In parallel with the accelerated time to market integration, the parties are also working on a full integration of the MyFiziq SDKs (Software Development Kit) into the new platform that Biomorphik is developing.
With a target release date of March quarter 2021, the new MyFiziq integrated Biomorphik platform will also include multi-language versions to target specific countries in Asia.
All aspects of new product to be customisable
All of MyFiziq's standard SDKs are included in the OnDemand version meaning that users have access to all the latest functionality offered by MyFiziq.
Meanwhile, authentication and payment options remain on the partner application.
This ensures that the OnDemand application can only be accessed via a partner application.
The OnDemand application has also been developed to be fully configurable by partners.
This means that branding, fonts and imagery as indicated below are fully customisable ensuring that user experience remains consistent between apps.
Targeting 100,000 active users in first 12 months
Commenting on this development, MyFiziq chief executive Vlado Bosanac said, “Biomorphik is our first partner to take advantage of our newly developed Body Scan OnDemand cross-linked iOS and Android applications, which we have built to get integrated products to market quicker, in turn enabling swifter user revenue generation for MyFiziq and our partners.
‘’As announced in August, Biomorphik originally confirmed a January 2021 MyFiziq integrated release.
‘’However, since then, Biomorphik has experienced a surge of new business interest in Asia due to the COVID-19 pandemic.
‘’In response to the surge in demand, we are now working with Nathaniel and his team to release the initial product to market by November 10, 2020, 3 months earlier than originally advised.’’
In conjunction with the express to market product, MyFiziq’s marketing team is assisting with a campaign to drive users throughout Asia to the Biomorphik platform.
The joint marketing campaign will focus on both user acquisition as user engagement and is targeted to commence in-line with the November 2020 release.
Biomorphik has undertaken a user target of 100,000 active users in the first 12 months and MyFiziq will play a role in achieving this target with a joint marketing campaign.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.